A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
Status:
Completed
Trial end date:
2019-04-25
Target enrollment:
Participant gender:
Summary
This is an open label, multicenter study designed to evaluate the safety and tolerability of
ATI-502 Topical Solution in male and female subjects with moderate or severe atopic
dermatitis (AD). Subjects will be required to apply ATI-502 study medication to their
identified AD treatment areas. All subjects will be required to complete a safety follow up
visit 4 weeks post last study medication application